We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Daptomycin: from the mountain to the clinic, with essential help from Francis Tally, MD.
- Authors
Eisenstein, Barry I; Oleson, Frederick B, Jr; Baltz, Richard H
- Abstract
Daptomycin has been approved and successfully launched for the treatment of complicated skin and skin-structure infections caused by gram-positive pathogens [1] and bacteremia and right-sided endocarditis due to Staphylococcus aureus, including strains that are resistant to methicillin or other antibiotics [2]. The development of the drug, however, was not straightforward; it involved a cast of characters, including scientists at Eli Lilly and at Cubist Pharmaceuticals. Of most importance, the development of daptomycin involved the tenacious leadership of Dr. Francis Tally. As a tribute to Dr. Tally, we attempt to reconstruct the path of daptomycin from the mountain to the clinic.
- Publication
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2010, Vol 50 Suppl 1, pS10
- ISSN
1537-6591
- Publication type
Journal Article
- DOI
10.1086/647938